JamesDBerryMD

Neurology • Boston, MA

Neuromuscular Medicine

Instructor, Neurology, Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Berry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Berry's full profile

Already have an account?

Office
55 Fruit St Fl 8
Boston, MA 02114
Phone+1 617-724-3914

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2006 - 2009
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2005 - 2006
Northwestern University The Feinberg School of MedicineClass of 2005

Certifications & Licensure

MA State Medical License 2009 - 2025
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Clinical Trials

A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers Start of enrollment: 2011 Nov 01
Completed
Gilenya in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Longitudinal Study of Outcomes Measures in ALS Trials Start of enrollment: 2013 Jul 01
Completed
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Start of enrollment: 2014 May 01
Completed
Phase 2
Open Label Extension Study of AMX0035 in Patients With ALS Start of enrollment: 2018 Mar 29
Completed
Phase 2
T-regulatory Cells in ALS Start of enrollment: 2019 Aug 07
Active, not recruiting
Phase 2
RAPA-501 Therapy for ALS Start of enrollment: 2024 Sep 01
Not yet recruiting
Phase 2, Phase 3
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Start of enrollment: 2021 Oct 15
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis.
James D Berry, Sabrina Paganoni, Matthew B Harms, Neil Shneider, Jinsy Andrews
Muscle & Nerve. 2024-12-01
Gastrostomy placement in patients with amyotrophic lateral sclerosis: assessment of risk factors for post-procedural respiratory failure.
Thomas J An, Sean Jang, Kalei Hering, Rafael Vazquez, Jennifer Scalia
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-11-01
Body mass index is lower in asymptomaticexpansion carriers but not inpathogenic variant carriers compared to gene negatives.
Ikjae Lee, Mark A Garret, Joanne Wuu, Elizabeth A Harrington, James D Berry
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-11-01

Press Mentions

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS AssociationNovember 19th, 2024
First Participant Enrolled in NIH-Funded Access for All in ALS ConsortiumAugust 12th, 2024
BrainStorm to Present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MNDNovember 23rd, 2020
Join now to see all